Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients

Blood

Volumn 118, Issue 24, 2011, Pages 6465-6466

  Carter, Clive R ^a   Feyler, Sylvia ^b   Smalle, Natuley ^a   Scott, Gina B ^b   Parrish, Christopher ^b   Cullen, Katherine ^a   Kallmeyer, Charlotte ^b,c   Wood, Philip M ^a   Cook, Gordon ^b,c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 2; LENALIDOMIDE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D;

CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 83455225450     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-372680     Document Type: Letter

References (7)

1. Hsu AK, Quach H, Tai T, Prince MK et al. The immuno-stimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117(5):1605-1613.
2. Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Antimyeloma activity of natural killer lymphocytes. Br J Haematol. 2002;119(3):660-664. (Pubitemid 35366205)
3. Carbone E, Neri P, Mesuraca M et al. HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251-258. (Pubitemid 40053090)
4. El-Sherbiny YM, Meade JL, Holmes TD et al. The requirement of DNAM-1, NKG2D, and NKp46 in the natural killer cell mediated killing of myeloma cells. Cancer Res. 2007;67(18):8444-8449. (Pubitemid 47437416)
5. Davies FE, Raje N, Hideshima T. Thalidomide and immunomodulatory derivatives augments natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
6. Carter CR, Savic S, Cole JY, Wood PMD. NK cell receptor expression in patients with severe and recurrent HSV-1 infections. Cell Immunol. 2007;246(2):65-74. (Pubitemid 47301778)
7. Gandhi AK, Kang J, Capone L et al. Dexamethasone synergises with lenalidomide to inhibit multiple myeloma tumor growth but reduces lenalidomide induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155-167.